News
Researchers at Sidney Kimmel Cancer Center at Thomas Jefferson University Promise New Directions for Targeting Prostate Cancer
A team of Sidney Kimmel Cancer Center (SKCC) investigators from Thomas Jefferson University and Drexel University has recently published a new study in the journal Cancer Research that sheds light on a key mechanism of prostate cancer progression.
Novel Small Molecule Sigma1 Inhibitors for Advanced Prostate Cancer
Salvino, JS, Oyer, HM, Kim, FJ, et al. Bioorganic & Medicinal Chemistry Letters.
Invented at Drexel: Startup Companies to Showcase New Drug Treatments at the Coulter Investment Forum
“Prostate cancer is a highly adaptive and constantly evolving disease. Ironically, treatment resistance is driven, in part, by the AR-targeted drugs that are designed specifically to suppress the disease,” said Felix Kim, PhD, assistant professor in the College of Medicine and co-founder of Context Therapeutics.